版本:
中国

BRIEF-Xenon Pharma says XEN801 did not meet endpoints in mid-stage study

March 24 Xenon Pharmaceuticals Inc:

* Xenon Pharmaceuticals announces XEN801 did not meet efficacy endpoints in phase 2 clinical trial in patients with moderate to severe acne

* Xenon Pharmaceuticals announces XEN801 did not meet efficacy endpoints in phase 2 clinical trial in patients with moderate to severe acne

* Xenon Pharmaceuticals Inc - XEN801 did demonstrate a favorable safety and tolerability profile, with no drug-related serious adverse events

* Xenon Pharmaceuticals Inc - results also show that xen801 did not demonstrate statistical significance relative to key secondary efficacy endpoints Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐